1α,25-Dihydroxyvitamin D3 enhances proliferation of rat prostate cancer cells in the presence of living bone

Paula A. Herring, Jesse Ingels, Genaro Palmieri, Karen Hasty

Research output: Contribution to journalArticle

Abstract

1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) is known to inhibit prostate cancer cells in vitro. Its effects on proliferation in the presence of living bone have not been reported, but are especially relevant since much of the morbidity and mortality associated with prostate cancer is due to metastatic bone disease. We investigated the effect of 1α,25(OH)2D3 on MatLyLu-β2 cells (MatLyLu cells), a rat prostate cancer line, co-cultured in transwells with living rat calvaria. Cultures of MatLyLu cells with living calvaria treated with 1α,25(OH)2D3 exhibited a statistically significant increase in proliferation (range 1.4 to 1.7-fold; p < 0.05). Cultures of MatLylu cells alone, with spleen cells, muscle tissue, or with living or inactivated calvarial bone showed no differences in proliferation. To investigate the mechanism for enhanced proliferation, Galardin, a matrix metalloproteinase (MMP) inhibitor, or pamidronate, an antiresorptive agent, was added. Enhanced proliferation was prevented by either agent, but not to an equal extent. The presence of 1α,25(OH)2D3 may lead to proteolytic release or activation of growth factors from bone. These results may explain the variability in reports on the in vivo effects of Vitamin D and suggest a potential concern in using Vitamin D or its analogs alone in patients with metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)737-741
Number of pages5
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume103
Issue number3-5
DOIs
StatePublished - Mar 1 2007

Fingerprint

Calcitriol
Rats
Prostatic Neoplasms
Bone
Cells
Bone and Bones
pamidronate
Skull
Vitamin D
Bone Density Conservation Agents
Matrix Metalloproteinase Inhibitors
Bone Diseases
Muscle
Intercellular Signaling Peptides and Proteins
Spleen
Cell Culture Techniques
Chemical activation
Tissue
Morbidity
Muscles

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology

Cite this

1α,25-Dihydroxyvitamin D3 enhances proliferation of rat prostate cancer cells in the presence of living bone. / Herring, Paula A.; Ingels, Jesse; Palmieri, Genaro; Hasty, Karen.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 103, No. 3-5, 01.03.2007, p. 737-741.

Research output: Contribution to journalArticle

@article{56db1715d1804fa286db18a747fc0a50,
title = "1α,25-Dihydroxyvitamin D3 enhances proliferation of rat prostate cancer cells in the presence of living bone",
abstract = "1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) is known to inhibit prostate cancer cells in vitro. Its effects on proliferation in the presence of living bone have not been reported, but are especially relevant since much of the morbidity and mortality associated with prostate cancer is due to metastatic bone disease. We investigated the effect of 1α,25(OH)2D3 on MatLyLu-β2 cells (MatLyLu cells), a rat prostate cancer line, co-cultured in transwells with living rat calvaria. Cultures of MatLyLu cells with living calvaria treated with 1α,25(OH)2D3 exhibited a statistically significant increase in proliferation (range 1.4 to 1.7-fold; p < 0.05). Cultures of MatLylu cells alone, with spleen cells, muscle tissue, or with living or inactivated calvarial bone showed no differences in proliferation. To investigate the mechanism for enhanced proliferation, Galardin, a matrix metalloproteinase (MMP) inhibitor, or pamidronate, an antiresorptive agent, was added. Enhanced proliferation was prevented by either agent, but not to an equal extent. The presence of 1α,25(OH)2D3 may lead to proteolytic release or activation of growth factors from bone. These results may explain the variability in reports on the in vivo effects of Vitamin D and suggest a potential concern in using Vitamin D or its analogs alone in patients with metastatic prostate cancer.",
author = "Herring, {Paula A.} and Jesse Ingels and Genaro Palmieri and Karen Hasty",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.jsbmb.2006.12.012",
language = "English (US)",
volume = "103",
pages = "737--741",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "3-5",

}

TY - JOUR

T1 - 1α,25-Dihydroxyvitamin D3 enhances proliferation of rat prostate cancer cells in the presence of living bone

AU - Herring, Paula A.

AU - Ingels, Jesse

AU - Palmieri, Genaro

AU - Hasty, Karen

PY - 2007/3/1

Y1 - 2007/3/1

N2 - 1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) is known to inhibit prostate cancer cells in vitro. Its effects on proliferation in the presence of living bone have not been reported, but are especially relevant since much of the morbidity and mortality associated with prostate cancer is due to metastatic bone disease. We investigated the effect of 1α,25(OH)2D3 on MatLyLu-β2 cells (MatLyLu cells), a rat prostate cancer line, co-cultured in transwells with living rat calvaria. Cultures of MatLyLu cells with living calvaria treated with 1α,25(OH)2D3 exhibited a statistically significant increase in proliferation (range 1.4 to 1.7-fold; p < 0.05). Cultures of MatLylu cells alone, with spleen cells, muscle tissue, or with living or inactivated calvarial bone showed no differences in proliferation. To investigate the mechanism for enhanced proliferation, Galardin, a matrix metalloproteinase (MMP) inhibitor, or pamidronate, an antiresorptive agent, was added. Enhanced proliferation was prevented by either agent, but not to an equal extent. The presence of 1α,25(OH)2D3 may lead to proteolytic release or activation of growth factors from bone. These results may explain the variability in reports on the in vivo effects of Vitamin D and suggest a potential concern in using Vitamin D or its analogs alone in patients with metastatic prostate cancer.

AB - 1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) is known to inhibit prostate cancer cells in vitro. Its effects on proliferation in the presence of living bone have not been reported, but are especially relevant since much of the morbidity and mortality associated with prostate cancer is due to metastatic bone disease. We investigated the effect of 1α,25(OH)2D3 on MatLyLu-β2 cells (MatLyLu cells), a rat prostate cancer line, co-cultured in transwells with living rat calvaria. Cultures of MatLyLu cells with living calvaria treated with 1α,25(OH)2D3 exhibited a statistically significant increase in proliferation (range 1.4 to 1.7-fold; p < 0.05). Cultures of MatLylu cells alone, with spleen cells, muscle tissue, or with living or inactivated calvarial bone showed no differences in proliferation. To investigate the mechanism for enhanced proliferation, Galardin, a matrix metalloproteinase (MMP) inhibitor, or pamidronate, an antiresorptive agent, was added. Enhanced proliferation was prevented by either agent, but not to an equal extent. The presence of 1α,25(OH)2D3 may lead to proteolytic release or activation of growth factors from bone. These results may explain the variability in reports on the in vivo effects of Vitamin D and suggest a potential concern in using Vitamin D or its analogs alone in patients with metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33947172497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947172497&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2006.12.012

DO - 10.1016/j.jsbmb.2006.12.012

M3 - Article

C2 - 17210249

AN - SCOPUS:33947172497

VL - 103

SP - 737

EP - 741

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 3-5

ER -